Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Programmed cell death protein 1, also known as PD-1 and CD279 (cluster of differentiation 279), is a cell surface receptor that plays an important role in down-regulating the immune system and promoting self tolerance by suppressing T cell inflammatory activity. PD-1 is an immune checkpoint and guards against autoimmunity through a dual mechanism of promoting apoptosis (programmed cell death) in antigen specific T-cells in lymph nodes while simultaneously reducing apoptosis in regulatory T cells (anti-inflammatory, suppressive T cells). PD-L1, the ligand for PD1, is highly expressed in several cancers and hence the role of PD1 in cancer immune evasion is well established. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer. Many tumor cells express PD-L1, an immunosuppressive PD-1 ligand; inhibition of the interaction between PD-1 and PD-L1 can enhance T-cell responses in vitro and mediate preclinical antitumor activity. This is known as immune checkpoint blockade. A number of cancer immunotherapy agents that target the PD-1 receptor have been developed. One such anti-PD-1 antibody drug, nivolumab, (Opdivo - Bristol Myers Squibb), produced complete or partial responses in non-small-cell lung cancer, melanoma, and renal-cell cancer, in a clinical trial with a total of 296 patients
Associated Disease
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
| XS-1022-ZP295 | Anti-PD-1 (PD1-0103) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | PD1-0103 | Mouse | scFv-41BB-CD52ζ | Lentiviral vector | T cell | ||
| XS-1022-ZP296 | Anti-PD-1 (PD1-0103) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | PD1-0103 | Mouse | scFv-CD28-CD52ζ | Lentiviral vector | T cell | ||
| XS-1022-ZP297 | Anti-PD-1 (PD1-F2) h(41BB-CD3ζ) CAR, pCDCAR1 | Mouse | PD1-F2 | Human | scFv-41BB-CD53ζ | Lentiviral vector | T cell | ||
| XS-1022-ZP298 | Anti-PD-1 (PD1-F2) h(CD28-CD3ζ) CAR, pCDCAR1 | Mouse | PD1-F2 | Human | scFv-CD28-CD53ζ | Lentiviral vector | T cell | ||
| XS-1022-ZP299 | Anti-PD-1 (PD1-17) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | PD1-17 | Human | scFv-41BB-CD52ζ | Lentiviral vector | T cell | ||
| XS-1022-ZP300 | Anti-PD-1 (PD1-17) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | PD1-17 | Human | scFv-CD28-CD52ζ | Lentiviral vector | T cell | ||
| XS-1022-ZP301 | Anti-PD-1 (PD1-0050) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | PD1-0050 | Mouse | scFv-41BB-CD53ζ | Lentiviral vector | T cell | ||
| XS-1022-ZP302 | Anti-PD-1 (PD1-0050) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | PD1-0050 | Mouse | scFv-CD28-CD53ζ | Lentiviral vector | T cell | ||
| XS-1022-ZP303 | Anti-PD-1 (PD1-0078) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | PD1-0078 | Mouse | scFv-41BB-CD54ζ | Lentiviral vector | T cell | ||
| XS-1022-ZP305 | Anti-PD-1 (PD1-45D6) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | PD1-45D6 | Human | scFv-41BB-CD53ζ | Lentiviral vector | T cell | ||
| XS-1022-ZP306 | Anti-PD-1 (PD1-45D6) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | PD1-45D6 | Human | scFv-CD28-CD53ζ | Lentiviral vector | T cell | ||
| XS-1022-ZP307 | Anti-PD-1 (PD1-0069) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | PD1-0069 | Mouse | scFv-41BB-CD54ζ | Lentiviral vector | T cell | ||
| XS-1022-ZP308 | Anti-PD-1 (PD1-0069) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | PD1-0069 | Mouse | scFv-CD28-CD54ζ | Lentiviral vector | T cell | ||
| XS-1022-ZP311 | Anti-PD-1 (1B8) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 1B8 | Mouse | scFv-41BB-CD54ζ | Lentiviral vector | T cell | ||
| XS-1022-ZP312 | Anti-PD-1 (1B8) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 1B8 | Mouse | scFv-CD28-CD54ζ | Lentiviral vector | T cell | ||
| XS-1022-ZP341 | Anti-PD-1 (H4H9048P2) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | H4H9048P2 | Humanized | scFv-41BB-CD59ζ | Lentiviral vector | T cell | ||
| XS-1022-ZP342 | Anti-PD-1 (H4H9048P2) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | H4H9048P2 | Humanized | scFv-CD28-CD59ζ | Lentiviral vector | T cell | ||
| XS-1022-ZP343 | Anti-PD-1 (76G5B3) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 76G5B3 | Human | scFv-41BB-CD60ζ | Lentiviral vector | T cell | ||
| XS-1022-ZP344 | Anti-PD-1 (76G5B3) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 76G5B3 | Human | scFv-CD28-CD60ζ | Lentiviral vector | T cell | ||
| XS-1022-ZP345 | Anti-PD-1 (NB01a) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | NB01a | Mouse | scFv-41BB-CD61ζ | Lentiviral vector | T cell | ||
| XS-0823-LX82 | Anti-hPD-1 (AB) ICD(CD28-OX40-CD3ζ) CAR-MA, pAd5f35 Vector | Human | AB | Adenoviral vectors |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
